{"result": "(\"entity\"<|>RETINOPATÍA DIABÉTICA<|>EVENT<|>Retinopathy is a diabetes complication that affects the eyes and can lead to vision loss if not managed properly.)\n##\n(\"entity\"<|>DMI<|>EVENT<|>DMI refers to multiple daily injections of insulin, a common treatment method for diabetes management.)\n##\n(\"entity\"<|>DM1<|>EVENT<|>DM1, or Type 1 Diabetes Mellitus, is a form of diabetes that occurs when the body does not produce insulin.)\n##\n(\"entity\"<|>DM2<|>EVENT<|>DM2, or Type 2 Diabetes Mellitus, is a form of diabetes that occurs when the body becomes resistant to insulin or does not produce enough insulin.)\n##\n(\"relationship\"<|>RETINOPATÍA DIABÉTICA<|>DIABETES<|>Retinopathy is a complication that can arise from poorly managed diabetes<|>8)\n##\n(\"relationship\"<|>DMI<|>DIABETES<|>DMI is a treatment method used for managing diabetes<|>7)\n##\n(\"relationship\"<|>DM1<|>DIABETES<|>DM1 is a type of diabetes that requires insulin management<|>9)\n##\n(\"relationship\"<|>DM2<|>DIABETES<|>DM2 is a type of diabetes that can be managed with various medications and lifestyle changes<|>9)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ponderal son los secretagogos (sulfonilureas, glinidas), la pioglitazona y el tratamiento con                                         previa del paciente. En general, estos suelen ser aproximadamente un 25-30% inferiores a\n         insulina.                                                                                                                             los del paciente en tratamiento con dosis múltiples de insulina (DMI).\n         La principal limitación para un adecuado control metabólico en pacientes en tratamiento                                               Comparación con las dosis múltiples de insulina\n         con insulina es la presencia de hipoglucemias, cuya incidencia aumenta al intensificar el                                             Dado el mayor coste de la terapia con ISCI, resulta recomendable no iniciar este tratamien-\n         tratamiento.                                                                                                                          to hasta que no se haya demostrado                  la falta de eficacia con DMI utilizando análogos de\n         Los   factores de riesgo para el desarrollo              y la progresión de la retinopatía diabética (RD)                             insulina en el contexto de una educación terapéutica optimizada. Dadas las limitaciones\n         incluyen un control glucémico deficiente, una larga duración de la diabetes y una presión                                             actuales para el uso de determinadas insulinas en el embarazo (glulisina, degludec), parece\n         arterial mal controlada. El efecto beneficioso del control glucémico estricto a largo plazo                                           razonable ofrecer esta terapia a pacientes con DM1, que no alcanzan con DMI los objetivos\n         en la prevención o retraso en el inicio o la progresión de la RD en pacientes con DM1 y                                               terapéuticos de HbA1c (<6-6,5%) antes de la gestación.\n         DM2 está establecida; sin embargo, las mejoras grandes y rápidas en el control glucémico\n         pueden asociarse con un empeoramiento transitorio de la RD, que a largo plazo puede con-\n         trarrestarse con la reducción de la RD con un mejor control glucémico.\n         La rotación en el lugar de inyección también es necesaria para evitar la lipohipertrofia y la li-\n         poatrofia. La lipohipertrofia puede contribuir a la absorción errática de insulina, al aumento\n         de la variabilidad glucémica y a los episodios de hipoglucemia inexplicables. Los pacientes\n         y/o cuidadores deben recibir educación sobre la rotación adecuada del sitio de inyección y\n         reconocer y evitar áreas de lipohipertrofia.\n         Referencias:\n         • Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the Diabetes Control and\n           Complications Trial. Arch Ophthalmol. 1998;116(7):874-86.\n         • Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl\n           1):S90-102.\n         • UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional\n           treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53.\n\n\n\n126                                                                                                                                                                                                                                                        127\n---\n                                                                                                                                                                                                                                                     DIABETES                            2\n\n\n\n         Tabla 9. Perfil farmacocinético               de las insulinas                                                                                de las necesidades de insulina también puede hacer necesario un descenso de la dosis de\n                              A favor de ISCI                                              Información adicional                                       ciertas terapias antidiabéticas hipoglucemiantes como repaglinida y las sulfonilureas.\n           Más eficaz con una reducción de la HbA1c del                Estos beneficios de la terapia con ISCI parecen ser                             Referencias:\n           0,5-0,6% según series                                       dependientes de la HbA1c (a mayor HbA1c, mayor beneficio)                       • American Diabetes Association. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes- 2019. Diabetes Care.\n                                                                                                                                                         2019;42(Suppl. 1):S173-81.\n                                                                       Parece disminuir hasta 4,2 veces. Mayores beneficios                            • Gómez-Huelgas R, Martínez-Castelao A, Artola S, Górriz JL, Menéndez E; en nombre del Grupo de Trabajo para el Documento de Con-\n                                                                                                                                                         senso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica. Treatment of type 2 diabetes mellitus in\n           Menor riesgo de hipoglucemia grave                          aparecen en aquellos pacientes con DMI con peor                                   patients with chronic kidney disease. Grupo de Trabajo para el Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en\n                                                                       control metabólico y más riesgo de hipoglucemias                                  el paciente con enfermedad renal crónica. Med Clin (Barc). 2014;142(2):85.e1-10.\n                                                                       graves\n           Menor incidencia de hipoglucemias no graves                 Hipoglucemias de menor gravedad disminuyen hasta\n                                                                       un\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>DIABETES<|>EVENT<|>Diabetes is a chronic condition that affects how the body processes blood sugar (glucose) and can lead to various complications if not managed properly.)\n##\n(\"entity\"<|>DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP<|>ORGANIZATION<|>The Diabetes Control and Complications Trial Research Group is a research organization that conducted studies on the effects of diabetes management on complications.)\n##\n(\"entity\"<|>AMERICAN DIABETES ASSOCIATION<|>ORGANIZATION<|>The American Diabetes Association is a leading organization that provides guidelines and standards for diabetes care and management.)\n##\n(\"entity\"<|>UK PROSPECTIVE DIABETES STUDY GROUP<|>ORGANIZATION<|>The UK Prospective Diabetes Study Group is a research group that studied the long-term effects of diabetes treatment on complications.)\n##\n(\"entity\"<|>INSULIN<|>EVENT<|>Insulin is a hormone that regulates blood sugar levels and is used in the treatment of diabetes.)\n##\n(\"entity\"<|>SULFONYLUREAS<|>EVENT<|>Sulfonylureas are a class of medications used to treat type 2 diabetes by increasing insulin production from the pancreas.)\n##\n(\"entity\"<|>GLINIDAS<|>EVENT<|>Glinides are a class of medications that stimulate insulin secretion from the pancreas and are used to manage blood sugar levels in diabetes.)\n##\n(\"entity\"<|>PIOGLITAZONA<|>EVENT<|>Pioglitazone is a medication used to treat type 2 diabetes by improving insulin sensitivity.)\n##\n(\"relationship\"<|>DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP<|>DIABETES<|>The Diabetes Control and Complications Trial Research Group conducted research on diabetes management and its complications<|>8)\n##\n(\"relationship\"<|>AMERICAN DIABETES ASSOCIATION<|>DIABETES<|>The American Diabetes Association provides guidelines for the management of diabetes<|>7)\n##\n(\"relationship\"<|>UK PROSPECTIVE DIABETES STUDY GROUP<|>DIABETES<|>The UK Prospective Diabetes Study Group studied the effects of diabetes treatment on complications<|>8)\n##\n(\"relationship\"<|>INSULIN<|>DIABETES<|>Insulin is a critical treatment for managing diabetes<|>9)\n##\n(\"relationship\"<|>SULFONYLUREAS<|>DIABETES<|>Sulfonylureas are used to treat type 2 diabetes by increasing insulin production<|>7)\n##\n(\"relationship\"<|>GLINIDAS<|>DIABETES<|>Glinides are used to manage blood sugar levels in diabetes<|>7)\n##\n(\"relationship\"<|>PIOGLITAZONA<|>DIABETES<|>Pioglitazone is a medication that helps improve insulin sensitivity in diabetes patients<|>7)\n<|COMPLETE|>"}]}